Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Phase 1

Completed

• Conditions: Healthy Subjects
• Interventions: Drug: LX4211 400 mg; Drug: canagliflozin 300 mg; Drug: LX4211 Placebo

• Registration Number: NCT01916863
• Lead Sponsor: Lexicon Pharmaceuticals

Brief Summary

The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-07-29
• Study Start: 2013-08
• Study First Submitted QC: 2013-08-02
• Study First Posted: 2013-08-06
• Status Verified: 2013-10
• Primary Completion: 2013-10
• Last Update Submitted: 2013-10-28
• Last Update Posted: 2013-10-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Adult subjects ≥18 to ≤55 years of age
• Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm
• Body mass index (BMI) ≥18 and ≤35 kg/sq m
• Willing and able to provide written informed consent

Exclusion Criteria

• Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 7 days of dosing
• Use of any investigational agent or study treatment within 30 days of Day -1
• Use of any protein or antibody-based therapeutic agents within 3 months of Screening
• Prior exposure to LX4211 or canagliflozin
• Daily use of >5 cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study
• History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption
• History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI procedure for the purpose of weight loss which would slow gastric emptying
• History of any major surgery within 6 months prior to Screening
• History of any hypersensitivity to the inactive components of LX4211, inactive components of canagliflozin, acetaminophen oral solution or any inactive component of acetaminophen liquid preparation
• History of renal disease or significantly abnormal kidney function tests
• History of hepatic disease or significantly abnormal liver function tests
• History of any active infection within 30 days prior to Day -1
• History of alcohol or substance abuse within 2 years prior to Day 1
• History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2
• Donation or loss of >500 mL of blood or blood product within 56 days of Day -1
• positive pregnancy test at Screening or Day -1
• Positive urine screen for drugs of abuse at Screening or Day -1
• Positive breath test for alcohol at Screening or Day -1
• Inability or difficulty swallowing whole tablets
• Unable or unwilling to communicate or cooperate with the Investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
LX4211	LX4211 400 mg	400 mg of LX4211
LX4211	canagliflozin 300 mg	400 mg of LX4211
LX4211	LX4211 Placebo	400 mg of LX4211
Canagliflozin	LX4211 400 mg	300 mg canagliflozin
Canagliflozin	canagliflozin 300 mg	300 mg canagliflozin
Canagliflozin	LX4211 Placebo	300 mg canagliflozin
Placebo	LX4211 400 mg	LX4211 placebo
Placebo	canagliflozin 300 mg	LX4211 placebo
Placebo	LX4211 Placebo	LX4211 placebo

Primary Outcome Measures

Name	Time	Method
Change from baseline in rate of glucose appearance after meal (RaO)	Days 1, 8, 15

Secondary Outcome Measures

Name	Time	Method
Rate of total glucose appearance (RaT)	Days 1, 8, 15
Change from baseline in fasting plasma glucose	Days 1, 8, 15
Change from baseline in postprandial glucose	Days 1, 8, 15
Change from baseline in insulin	Days 1, 8, 15

Trial Locations

Locations (1)

Lexicon Investigational Site; 🇺🇸 Chula Vista, California, United States